Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Glycogen Storage Diseases and Metabolic Disorder Therapeutics Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GYS1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GYS1 Active Recombinant Protein High purity (>95%), Endotoxin Controlled (<1EU/ug). Sequence Verified. Suitable for enzymatic activity and biophysical binding assays. |
View GYS1 Products |
| Gene Delivery | GYS1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based glycogen accumulation assays. |
View GYS1 Products |
| Benchmark Ab | Anti-GYS1 Recombinant Antibody Recombinant positive control for Western Blot, ELISA, and intracellular flow cytometry. |
View GYS1 Products |
| Validator | GYS1 siRNA Set Sequence-verified siRNA pool for target knockdown verification in disease models. |
View GYS1 Products |
| Related Target A | GYS2 (Glycogen Synthase 2) Liver-specific isoform. Crucial counter-screening target to ensure GYS1-specific selectivity and avoid hepatic hypoglycemia risk. |
View GYS2 Products |
| Related Target B | GSK3B (Glycogen Synthase Kinase 3 Beta) Primary upstream regulatory kinase that phosphorylates and inactivates GYS1. Key target for synergistic pathway modulation. |
View GSK3B Products |
| Related Target C | GYG1 (Glycogenin 1) Self-glucosylating initiator protein that primes glycogen synthesis before GYS1 elongation. |
View GYG1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (GYS1 vs. GYS2) | Highly purified, active GYS1 and GYS2 recombinant proteins available with verified sequence identity by Mass Spectrometry. |
| Phosphorylation-State Sensitivity | Expression systems designed to yield defined phosphorylation states, enabling robust testing of allosteric (G6P-dependent) and non-allosteric inhibitors. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies and validated siRNA sets included for assay normalization. |
| Conformation-Sensitive Screening | High-titer Lentiviral particles for stable cell line generation, preserving native cytoplasmic GYS1 complex conformations. |
Live GYS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GYS1 (Glycogen Synthase 1) is rapidly gaining momentum, transitioning from a theoretical metabolic node to a clinically validated strategy. GYS1 catalyzes the final step in glycogen synthesis in skeletal muscle and the brain. Its chronic over-activation is a primary driver of toxic glycogen accumulation in severe neuromuscular and neurodegenerative disorders, such as Pompe disease (Glycogen Storage Disease Type II) and Lafora disease (Progressive Myoclonus Epilepsy).
The race for GYS1 therapeutics is intensifying, with major players shifting focus from traditional enzyme replacement therapies to substrate reduction therapies (SRT) using brain-penetrant small molecule inhibitors and targeted RNA therapeutics (siRNA/ASO). As first-generation systemic therapies reach late-stage clinical evaluation, the next wave of R&D is targeting highly selective, blood-brain barrier-crossing molecules to address the devastating CNS manifestations of glycogen accumulation.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitor) | Maze Therapeutics, Shier/Takeda, Astellas | Pompe Disease, Lafora Disease | Selectivity Assay (Need high-purity GYS1 vs GYS2 recombinant proteins to avoid liver toxicity) |
| RNA Therapeutics (siRNA / ASO) | Alnylam Pharmaceuticals, Ionis Pharmaceuticals | Lafora Disease, GSD II | In vitro Knockdown Validation (Need sequence-verified GYS1 siRNA and overexpressing Lentivirus) |
| Gene Therapy / Editing | Academic Consortia, Biotech Startups | APBD (Adult Polyglucosan Body Disease) | Expression Rescue Validation (Need high-affinity benchmark antibodies for Western Blot/IHC) |